Ustekinumab Biosimilar, IL-12 / IL-23 Monoclonal Antibody

Additional Information:
| Ustekinumab Biosimilar, IL-12 / IL-23 Monoclonal Antibody Recombinant Humanized IgG1 Monoclonal Antibody. |Isotype: Human IgG1 lambda. |Source: The anti-human IL-12 / IL-23 monoclonal antibody ustekinumab biosimilar was produced in mammal cells. |Specificity/Sensitivity: The in vivo grade ustekinumab biosimilar specifically binds to the human interleukin-12 (IL-12) and interleukin-23 (IL-23). |Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological |0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives. |Endotoxin: |Purity: >95% by SDS-|The research grade ustekinumab biosimilar is shipped with ice |Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied. |Background What is Ustekinumab Biosimilar research grade? Ustekinumab is a human anti-IL-12 / IL-23 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. It targets and neutralize interleukin-12 and interleukin-23, two proteins assoc with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha. Ustekinumab represents a novel approach to treating psor Multiple Sclerosis, Crohn’s Disease and other autoimmune and inflammatory disorders. Ustekinumab biosimilar uses the same protein sequences as the therapeutic antibody ustekinumab. Syd Labs also provides the following anti-IL antibody biosimilar proteins: Pascolizumab Biosimilar, research grade, anti-human IL-4 monoclonal antibody Sarilumab Biosimilar, research grade, anti-human IL-6/IL-6R monoclonal antibody Secukinumab Biosimilar, research grade, anti-human IL-17/IL-17a monoclonal antibody Tocilizumab Biosimilar, research grade, anti-human IL-6/IL-6R monoclonal antibody Br Biosimilar, research grade, anti-human IL-12/IL-23 monoclonal antibody